Innovate UK award BioMoti, Pharmidex and Queen Mary University of London Biomedical Catalyst grant
December 5, 2017

Exciting project involving BioMoti, Pharmidex and Queen Mary University.

BioMoti (London, UK), Pharmidex (London, UK) and Queen Mary University of London (London, UK) have been awarded a grant of £662,222 following the Biomedical Catalyst funding competition from Innovate UK (Swindon, UK).


The grant was awarded to support the preclinical studies of the development of novel therapeutic approaches for hard to treat tumors, including advanced ovarian, triple negative breast and pancreatic cancers. Cofunded by a further £226,769 investment from BioMoti and Pharmidex, the project focuses on Oncojan™ from BioMoti, described as a ‘sustained release precision therapeutics platform targeting CD95L mediated tumor immune evasion’. With expertise in preclinical drug development from Pharmidex and mechanisms of disease from Queen Mary University of London, the trio will investigate precision delivery of drugs to solid tumor sites and immune system activation due to CD95L targeting on tumors over the next 2 years. “It is exciting for us to be supported by Innovate UK to explore our platform’s interactions with the immune system following promising efficacy data in cancer models. BioMoti is making great progress on a final seed investment round to support commercialisation and we welcome enquiries from qualified investors,” commented Davidson Ateh (BioMoti). “We are very pleased to join BioMoti and Queen Mary University of London in the preclinical development of the Oncojan™ platform.


This Innovate UK funded project is an exciting approach to cancer therapy that could have a significant impact on patient lives,” stated Chris Ireson (Pharmidex). “We are passionate about what a difference we could make for patients, and it is great to have secured Innovate UK funding,” concluded Joanne Martin (Queen Mary University of London).


 


Please see the link for more information: www.biomoti.com/biomoti-pharmidex-and-queen-mary-university-of-london-secure-662222-biomedical-catalyst-award/

Funding Opportunity for Early-Stage Innovators in Scotland

May 1, 2026
Early-stage innovators based in Scotland have access to a significant opportunity to advance their programs toward ProofOfConcept, with an additional £2.85M fund from the Scottish Government aimed at supporting early development and enabling further investment. 🗓️ Deadline: 8th May At Pharmidex , we work alongside our partners to generate robust, translational data that supports confident decision-making across early discovery and preclinical development. Our capabilities include: TargetExpression ModeOfActionStudies TargetEngagement HitIdentification ADME and PK profiling If you are preparing an application and require scientific input or timely quotations, we would be pleased to support your programme. 🔗 https://lnkd.in/eZ6vVjgN

We’re pleased to introduce the Pharmidex Senior Management Team

April 29, 2026
We’re pleased to introduce the Pharmidex Senior Management Team (SMT), bringing together expertise across drug discovery, bioanalysis, DMPK, and translational science: 🔹 Alix Hampson 🔹 Dr Mansoor Chishty 🔹 Prof Mo Alavijeh (FRSC, FRSM) 🔹 Dr Martin Barrett 🔹 Dr Stephen Mitchell 🔹 Ash Alavijeh Collectively, the team brings 150+ years of combined experience, supporting programmes from discovery through to the clinic and beyond. We’ve also seen firsthand how similar pieces, in the hands of our 400+ innovative clients, can be combined to unlock real impact for patients. To mark the occasion, we’ve reimagined our SMT in LEGO style 🧱 Much like LEGO: • Great things are built step by step • Every piece has a purpose • The best outcomes come from creativity, collaboration, and continuous evolution At Pharmidex, it’s about bringing the right pieces together, to build smarter solutions and better outcomes.

Tailored Genetically Altered Breeding Solutions at Pharmidex

April 27, 2026
The success of your research starts with the right model, at the right time. At Pharmidex, we deliver tailored GA breeding solutions combining expert colony management, flexible study design, and rigorous quality control. Backed by AAALAC-accredited facilities and a strong commitment to the 3Rs, we ensure reliable, study-ready models with full traceability. From breeding strategy and genotyping to scalable capacity and flexible timelines, we act as an extension of your team, helping accelerate your research with confidence. 🔬 The right models. When you need them. 🚀 Flexible. Reliable. Research-focused. Let’s build your next breeding strategy.
More Posts